title: Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression.
abstract: OBJECTIVE
  Radiofrequency ablation (RFA) is a minimally invasive energy delivery technique increasingly used for focal therapy to eradicate localized disease. RFA-induced tumor-cell necrosis generates an immunogenic source of tumor antigens known to induce antitumor immune responses. However, RFA-induced antitumor immunity is insufficient to control metastatic progression. We sought to characterize (a) the role of RFA dose on immunogenic modulation of tumor and generation of immune responses and (b) the potential synergy between vaccine immunotherapy and RFA aimed at local tumor control and decreased systemic progression.
  
  
  METHODS
  Murine colon carcinoma cells expressing the tumor-associated (TAA) carcinoembryonic antigen (CEA) (MC38-CEA(+)) were studied to examine the effect of sublethal hyperthermia in vitro on the cells' phenotype and sensitivity to CTL-mediated killing. The effect of RFA dose was investigated in vivo impacting (a) the phenotype and growth of MC38-CEA(+) tumors and (b) the induction of tumor-specific immune responses. Finally, the molecular signature was evaluated as well as the potential synergy between RFA and poxviral vaccines expressing CEA and a TRIad of COstimulatory Molecules (CEA/TRICOM).
  
  
  RESULTS
  In vitro, sublethal hyperthermia of MC38-CEA(+) cells (a) increased cell-surface expression of CEA, Fas, and MHC class I molecules and (b) rendered tumor cells more susceptible to CTL-mediated lysis. In vivo, RFA induced (a) immunogenic modulation on the surface of tumor cells and (b) increased T-cell responses to CEA and additional TAAs. Combination therapy with RFA and vaccine in CEA-transgenic mice induced a synergistic increase in CD4(+) T-cell immune responses to CEA and eradicated both primary CEA(+) and distal CEA(-) s.c. tumors. Sequential administration of low-dose and high-dose RFA with vaccine decreased tumor recurrence compared to RFA alone. These studies suggest a potential clinical benefit in combining RFA with vaccine in cancer patients, and augment support for this novel translational paradigm.
authors.affiliation: Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
authors.forename: Sofia R
authors.initials: SR
authors.lastname: Gameiro
authors.forename: Jack P
authors.initials: JP
authors.lastname: Higgins
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Dreher
authors.forename: David L
authors.initials: DL
authors.lastname: Woods
authors.forename: Goutham
authors.initials: G
authors.lastname: Reddy
authors.forename: Bradford J
authors.initials: BJ
authors.lastname: Wood
authors.forename: Chandan
authors.initials: C
authors.lastname: Guha
authors.forename: James W
authors.initials: JW
authors.lastname: Hodge
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002272:Carcinoembryonic Antigen / Q000276:immunology*; D017115:Catheter Ablation; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000601:surgery* / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic
chemical_list: D019496:Cancer Vaccines; D002272:Carcinoembryonic Antigen
references.citation: Int J Oncol. 2011 Aug;39(2):311-8
references.pmid: 21573504
references.citation: Intervirology. 2005;48(1):64-70
references.pmid: 15785092
references.citation: Science. 1997 Aug 8;277(5327):818-21
references.pmid: 9242611
references.citation: Cancer Res. 1991 Jul 15;51(14):3657-62
references.pmid: 1712245
references.citation: Blood. 2009 Mar 26;113(13):3008-16
references.pmid: 19018093
references.citation: FEBS J. 2012 Oct;279(20):3800-12
references.pmid: 22883469
references.citation: Dig Surg. 2008;25(6):445-60
references.pmid: 19212117
references.citation: Int J Cancer. 2013 Aug 1;133(3):624-36
references.pmid: 23364915
references.citation: J Immunol. 2013 Jun 15;190(12):6550-8
references.pmid: 23690481
references.citation: Int J Oncol. 2008 Feb;32(2):481-90
references.pmid: 18202772
references.citation: Cancer Res. 2004 Jun 1;64(11):4024-9
references.pmid: 15173017
references.citation: Acad Radiol. 2007 Jul;14(7):859-70
references.pmid: 17574136
references.citation: Clin Cancer Res. 2008 Jul 1;14(13):4241-9
references.pmid: 18594006
references.citation: Cancer Res. 2003 Nov 15;63(22):7942-9
references.pmid: 14633725
references.citation: J Natl Cancer Inst. 1995 Jul 5;87(13):982-90
references.pmid: 7629885
references.citation: J Vasc Interv Radiol. 2009 Jul;20(7 Suppl):S342-7
references.pmid: 19560023
references.citation: Eur J Immunol. 1999 Oct;29(10):3295-301
references.pmid: 10540341
references.citation: Cancer Res. 1994 Aug 1;54(15):4169-76
references.pmid: 8033149
references.citation: Radiology. 2009 Apr;251(1):58-66
references.pmid: 19251937
references.citation: Clin Cancer Res. 2005 Mar 15;11(6):2416-26
references.pmid: 15788693
references.citation: Clin Cancer Res. 2006 Mar 15;12(6):1897-905
references.pmid: 16551875
references.citation: Biotechnol Ther. 1993;4(3-4):163-81
references.pmid: 8292968
references.citation: Int J Cancer. 2011 Jun 1;128(11):2653-62
references.pmid: 20715115
references.citation: Curr Med Chem. 2012;19(12):1765-70
references.pmid: 22414085
references.citation: J Biol Chem. 2007 Oct 26;282(43):31688-702
references.pmid: 17684010
references.citation: Ultrasound Med Biol. 2012 Aug;38(8):1363-71
references.pmid: 22633269
references.citation: Tumour Biol. 2003 Jan-Feb;24(1):32-9
references.pmid: 12743424
references.citation: J Immunother. 2008 Jan;31(1):63-71
references.pmid: 18157013
references.citation: Eur Radiol. 2012 May;22(5):1091-100
references.pmid: 22105843
references.citation: Anticancer Res. 2007 Mar-Apr;27(2):841-50
references.pmid: 17465210
references.citation: Oncogene. 2013 Jun 6;32(23):2891-9
references.pmid: 22869146
references.citation: Cancer. 2002 Jan 15;94(2):443-51
references.pmid: 11900230
references.citation: J Gastroenterol. 2010 Apr;45(4):451-8
references.pmid: 19936602
references.citation: Cancer Res. 1985 Nov;45(11 Pt 2):5769-80
references.pmid: 2413997
references.citation: Carcinogenesis. 2011 Dec;32(12):1832-9
references.pmid: 21983127
references.citation: Semin Oncol. 2012 Jun;39(3):296-304
references.pmid: 22595052
references.citation: Hepatobiliary Pancreat Dis Int. 2010 Aug;9(4):361-5
references.pmid: 20688598
references.citation: Cancer Res. 2002 Sep 1;62(17):5058-64
references.pmid: 12208761
references.citation: Cancer Immunol Immunother. 2008 Dec;57(12):1827-35
references.pmid: 18438666
references.citation: Radiat Res. 2012 Sep;178(3):105-17
references.pmid: 22827214
references.citation: Semin Oncol. 2012 Jun;39(3):323-39
references.pmid: 22595055
references.citation: Int J Hyperthermia. 2012;28(8):766-75
references.pmid: 23043501
references.citation: Dig Dis Sci. 2010 Aug;55(8):2365-72
references.pmid: 19830559
references.citation: Cancer Immunol Immunother. 2001 Jan;49(11):603-12
references.pmid: 11225991
references.citation: Liver Int. 2009 Jan;29(1):18-24
references.pmid: 19018971
references.citation: Cancer Res. 2004 Nov 1;64(21):7985-94
references.pmid: 15520206
references.citation: Ann Surg Oncol. 2008 Jan;15(1):144-57
references.pmid: 17906898
references.citation: Mol Cancer Res. 2013 Jan;11(1):5-12
references.pmid: 23175523
references.citation: Ann Surg. 2010 May;251(5):796-803
references.pmid: 19858704
references.citation: Cancer Biother Radiopharm. 2012 Feb;27(1):12-22
references.pmid: 22283603
references.citation: Radiology. 2009 Apr;251(1):1-2
references.pmid: 19332838
references.citation: Cancer Res. 2004 Jun 15;64(12):4328-37
references.pmid: 15205348
references.citation: Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15312-7
references.pmid: 22949650
references.citation: J Exp Clin Cancer Res. 2012 Jun 19;31:58
references.pmid: 22713668
references.citation: Cancer Lett. 2012 Dec 28;325(2):117-24
references.pmid: 22750096
references.citation: Ann Surg Oncol. 2004 Apr;11(4):399-406
references.pmid: 15070600
references.citation: Cancer Res. 2006 Jan 15;66(2):1139-46
references.pmid: 16424051
references.citation: Clin Cancer Res. 1997 Dec;3(12 Pt 1):2439-49
references.pmid: 9815645
references.citation: Immunity. 1994 Aug;1(5):357-64
references.pmid: 7533644
references.citation: Oncogene. 2013 Jan 17;32(3):296-306
references.pmid: 22370643
references.citation: Colorectal Dis. 2011 Sep;13(9):e252-65
references.pmid: 21689362
references.citation: Cancer Res. 2001 Jan 1;61(1):206-14
references.pmid: 11196163
references.citation: Clin Cancer Res. 2008 Jul 1;14(13):4316-25
references.pmid: 18594015
references.citation: Clin Dev Immunol. 2011;2011:160250
references.pmid: 22242035